Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Net Income (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Net Income data on record, last reported at -$17.8 million in Q1 2026.

  • On a quarterly basis, Net Income fell 22.22% to -$17.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$55.2 million, a 43.78% decrease, with the full-year FY2025 number at -$52.0 million, down 81.8% from a year prior.
  • Net Income reached -$17.8 million in Q1 2026 per IKT's latest filing, down from -$13.8 million in the prior quarter.
  • Over the last five years, Net Income for IKT hit a ceiling of -$4.3 million in Q4 2022 and a floor of -$17.8 million in Q1 2026.
  • A 5-year average of -$8.0 million and a median of -$5.1 million in 2024 define the central range for Net Income.
  • Peak YoY movement for Net Income: rose 18.57% in 2024, then plummeted 205.25% in 2025.
  • Tracing IKT's Net Income over 5 years: stood at -$4.3 million in 2022, then dropped by 1.58% to -$4.4 million in 2023, then plummeted by 193.6% to -$12.9 million in 2024, then fell by 6.55% to -$13.8 million in 2025, then decreased by 29.52% to -$17.8 million in 2026.
  • Business Quant data shows Net Income for IKT at -$17.8 million in Q1 2026, -$13.8 million in Q4 2025, and -$12.8 million in Q3 2025.